Daniele Zonari

Daniele Zonari

Auto-generated profile, based on publicly available information

Daniele Zonari

Department of Drug Science and Technology, University of Torino, Via P. Giuria 9, Torino, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
VRValentina Ricci
Valentina Ricci
DZDaniele Zonari
Daniele Zonari
Stefania CannitoStefania Cannito
Stefania Cannito
AMAlessandro Marengo
Alessandro Marengo
Maria Teresa ScupoliMaria Teresa Scupoli
Maria Teresa Scupoli
Silvia ArpiccoSilvia Arpicco
Silvia Arpicco

1 October 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
APAgnese C. Pippione
Agnese C. Pippione
Alessandro GiraudoAlessandro Giraudo
Alessandro Giraudo
DBDavide Bonanni
Davide Bonanni
ICIrene M. Carnovale
Irene M. Carnovale
EMElisabetta Marini
Elisabetta Marini
MLMarco L. Lolli
Marco L. Lolli
The aldo-keto reductase 1C3 isoform (AKR1C3) plays a vital role in the biosynthesis of androgens, making this enzyme an attractive target for castration-resistant prostate cancer therapy. Although AKR1C3 is a promising drug target, no AKR1C3-targeted agent has to date been approved for clinical use. Flufenamic acid, a non-steroidal anti-inflammatory drug, is known to potently inhibit AKR1C3 in a non-selective manner as COX off-target effects are also observed. To diminish off-target effects, we have applied a scaffold hopping strategy replacing the benzoic acid moiety of flufenamic acid with an acidic hydroxyazolecarbonylic scaffold. In particular, differently N-substituted hydroxylated triazoles were designed to simultaneously interact with both subpockets 1 and 2 in the active site of AKR1C3, larger for AKR1C3 than other AKR1Cs isoforms. Through computational design and iterative rounds of synthesis and biological evaluation, novel compounds are reported, sharing high selectivity (up to 230-fold) for AKR1C3 over 1C2 isoform and minimal COX1 and COX2 off-target inhibition. A docking study of compound 8, the most interesting compound of the series, suggested that its methoxybenzyl substitution has the ability to fit inside subpocket 2, being involved in π-π staking interaction with Trp227 (partial overlapping) and in a T-shape π-π staking with Trp86. This compound was also shown to diminish testosterone production in the AKR1C3-expressing 22RV1 prostate cancer cell line while synergistic effect was observed when 8 was administered in combination with abiraterone or enzalutamide.

1 January 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
Franco DosioFranco Dosio
Franco Dosio
Barbara StellaBarbara Stella
Barbara Stella
AFAnnalisa Ferrero
Annalisa Ferrero
CGClaudio Garino
Claudio Garino
DZDaniele Zonari
Daniele Zonari
GRGobetto Roberto
Gobetto Roberto
Transition metal complexes provide a promising avenue for designing new therapeutic and diagnostic agents. In particular, ruthenium(II) polypyridyl complexes are useful for studying cellular uptake, due to their easy synthesis and unique photophysical properties. Dyes are frequently combined with material substrates to modulate their properties, enhance stability, reduce toxicity, and improve delivery. A novel Ru polypyridyl complex linked to a derivative of the natural lipid squalene (Ru-BIPPBI-hx-SQ) is described. Using the solvent displacement method, Ru-BIPPBI-hx-SQ easily self-assembles into nanosized aggregates in aqueous solution, as characterized by dynamic light scattering. The nanoassemblies exhibit long-lived and intense luminescence. Preliminary biological assessment showed them to be non-toxic; they are efficiently and rapidly transported across the cell membrane without requiring its permeabilization. Ru-labeled nanoassemblies are likely to be significant cellular-imaging tools, probing cellular events at very low concentrations. Moreover co-nanoassembly, with drug-derivatives based on squalenoylation technology, including gemcitabine and paclitaxel, has given interesting preliminary results.